On December 14, 2017 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) as part of the NBI’s annual re-ranking of biotechnology and pharmaceutical companies listed on The NASDAQ Stock Market (NASDAQ) that meet NBI’s eligibility criteria (Press release, Puma Biotechnology, DEC 14, 2017, View Source [SID1234522653]). Puma will be added to the NBI effective prior to market open on Monday, December 18, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB) and is re-ranked annually in December.